# Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

> **NCT01109121** · PHASE2 · COMPLETED · sponsor: **Nuon Therapeutics, Inc.** · enrollment: 112 (actual)

## Conditions studied

- Moderate to Severe Gout
- Hyperuricemia

## Interventions

- **DRUG:** Combination 400
- **DRUG:** Allopurinol
- **DRUG:** Combination 600

## Key facts

- **NCT ID:** NCT01109121
- **Lead sponsor:** Nuon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2011-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109121, "Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01109121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*